Clinical data | |
---|---|
Other names | PD-0332334; PD-332,334 |
ATC code |
|
Identifiers | |
| |
CAS Number |
|
PubChem CID | |
ChemSpider | |
UNII | |
KEGG | |
CompTox Dashboard (EPA) | |
Chemical and physical data | |
Formula | C9H19NO2 |
Molar mass | 173.256 g·mol−1 |
3D model (JSmol) | |
| |
|
Imagabalin (INN, USAN; PD-0332334) was an investigational drug that acted as a ligand for the α2δ subunit of the voltage-dependent calcium channel,[1] with some selectivity for the α2δ1 subunit over α2δ2.[2] It was under development by Pfizer as a pharmaceutical medication due to its hypothesized anxiolytic, analgesic, hypnotic, and anticonvulsant-like activity. It reached phase-III clinical trials for treatment of generalized anxiety disorder; however, the trials were terminated by the manufacturer.[3][4][5][6] The drug is no longer under development.
((cite journal))
: Cite journal requires |journal=
(help)
((cite journal))
: Cite journal requires |journal=
(help)
((cite journal))
: Cite journal requires |journal=
(help)
((cite journal))
: Cite journal requires |journal=
(help)
5-HT1AR agonists | |
---|---|
GABAAR PAMs |
|
Gabapentinoids (α2δ VDCC blockers) | |
Antidepressants |
|
Sympatholytics (Antiadrenergics) |
|
Others | |
|